BRIEF-Ophthotech announces results from phase 3 trial of Fovista
Aug 14 (Reuters) - Ophthotech Corp:
* Ophthotech announces results from third phase 3 trial of Fovista® in wet age-related macular degeneration
* Ophthotech corp - ‍pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved​
* Ophthotech - ‍did not observe any clinically meaningful visual benefit in pre-specified secondary endpoints when fovista was added to eylea or avastin regimen​
* Ophthotech - ‍addition of 1.5mg of Fovista to Eylea or avastinregimen did not result in benefit as per mean change in visual acuity at 12-month point​
* Ophthotech - ‍ocular adverse events more frequently reported in fovista combination therapy group compared to eylea or avastin monotherapy group were mainly related to injection procedure​
* Says ‍company has decided to stop treating patients who are in second year of oph1004 study​
* Ophthotech - ‍based on a preliminary analysis, fovista combination therapy & eylea or avastin monotherapy were generally well tolerated after 1 year Source text for Eikon: Further company coverage: